“Put it in the water!” — How a Toxic Tree May Save Thousands of Smokers

Based on Hunterbrook Media’s reporting, Hunterbrook Capital is long $ACHV at the time of publication. Positions may change at any time. See full disclosures below.

• Achieve Life Sciences ($ACHV) is a roughly $250 million medical company seeking FDA approval for cytisinicline, likely the best therapy to quit smoking. If approved on June 20, Achieve plans to sell the medicine in the U.S. by the end of 2026. The company is also seeking approval for the first therapy to help people quit vaping.
• The FDA accepted Achieve’s anti-smoking application for review, with two successful Phase 3 clinical trials and a successful longer-term safety study. The FDA also expedited anti-vaping with both a National Priority Voucher and Breakthrough Therapy Designation. If cytisinicline is approved for anti-smoking, it will likely also be approved for anti-vaping.
• Under the Affordable Care Act, nearly all American health plans must offer insurance coverage for FDA-approved smoking cessation interventions.
• Cytisinicline is already used in Europe. Several smoking cessation clinicians, scientists, and health program directors that Hunterbrook interviewed for this investigation said cytisinicline should